Second-site suppressor mutations reveal connection between the drug-binding pocket and nucleotide-binding domain 1 of human P-glycoprotein (ABCB1)

被引:5
|
作者
Murakami, Megumi [1 ]
Sajid, Andaleeb [1 ]
Lusvarghi, Sabrina [1 ]
Durell, Stewart R. [1 ]
Abel, Biebele [1 ]
Vahedi, Shahrooz [1 ]
Golin, John [2 ]
Ambudkar, Suresh V. [3 ]
机构
[1] NCI, NIH, Ctr Canc Res, Lab Cell Biol, Bethesda, MD 20892 USA
[2] Catholic Univ Amer, Dept Biol, Washington, DC 20064 USA
[3] NCI, Cell Biol Lab, Ctr Canc Res, NIH, 37 Convent Dr,Room 2120, Bethesda, MD 20892 USA
基金
美国国家卫生研究院; 日本学术振兴会;
关键词
ABC transporter; Multidrug resistance; P-glycoprotein; Second -site suppressors; Molecular dynamics simulations; MULTIDRUG-RESISTANCE; ATP HYDROLYSIS; CATALYTIC CYCLE; TRANSPORT; EXPRESSION; INHIBITION; SUBSTRATE; TRANSLOCATION; MODULATION; INTERFACE;
D O I
10.1016/j.drup.2023.101009
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Human P-glycoprotein (P-gp) or ABCB1 is overexpressed in many cancers and has been implicated in altering the bioavailability of chemotherapeutic drugs due to their efflux, resulting in the development of chemoresistance. To elucidate the mechanistic aspects and structure-function relationships of P-gp, we previously utilized a tyrosine (Y)-enriched P-gp mutant (15Y) and demonstrated that at least 15 conserved residues in the drug -binding pocket of P-gp are responsible for optimal substrate interaction and transport. To further understand the role of these 15 residues, two new mutants were generated, namely 6Y with the substitution of six residues (F72, F303, I306, F314, F336 and L339) with Y in transmembrane domain (TMD) 1 and 9Y with nine sub-stitutions (F732, F759, F770, F938, F942, M949, L975, F983 and F994) in TMD2. Although both the mutants were expressed at normal levels at the cell surface, the 6Y mutant failed to transport all the tested substrates except Bodipy-verapamil, whereas the 9Y mutant effluxed all tested substrates in a manner very similar to that of the wild-type protein. Further mutational analysis revealed that two second-site mutations, one in intracellular helix (ICH) 4 (F916Y) and one in the Q loop of nucleotide-binding domain (NBD) 1 (F480Y) restored the transport function of 6Y. Additional biochemical data and comparative molecular dynamics simulations of the 6Y and 6Y+F916Y mutant indicate that the Q-loop of NBD1 of P-gp communicates with the substrate-binding sites in the transmembrane region through ICH4.This is the first evidence for the existence of second-site suppressors in human P-gp that allow recovery of the loss of transport function caused by primary mutations. Further study of such mutations could facilitate mapping of the communication pathway between the substrate-binding pocket and the NBDs of P-gp and possibly other ABC drug transporters.
引用
收藏
页数:13
相关论文
共 50 条
  • [31] P-glycoprotein (ABCB1)- weak dipolar interactions provide the key to understanding allocrite recognition, binding, and transport
    Seelig, Anna
    Li-Blatter, Xiaochun
    CANCER DRUG RESISTANCE, 2023, 6 (01) : 1 - 29
  • [32] Allocrite Sensing and Binding by the Breast Cancer Resistance Protein (ABCG2) and P-Glycoprotein (ABCB1)
    Xu, Yanyan
    Egido, Estefania
    Li-Blatter, Xiaochun
    Mueller, Rita
    Merino, Gracia
    Berneche, Simon
    Seelig, Anna
    BIOCHEMISTRY, 2015, 54 (40) : 6195 - 6206
  • [33] Drug-stimulated ATPase activity of human P-glycoprotein is blocked by disulfide cross-linking between the nucleotide-binding sites
    Loo, TW
    Clarke, DM
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (26) : 19435 - 19438
  • [34] THE STEREOSELECTIVITY OF THE SINGLE DRUG-BINDING SITE OF HUMAN ALPHA-1-ACID GLYCOPROTEIN (OROSOMUCOID)
    BRUNNER, F
    MULLER, WE
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 1987, 39 (12) : 986 - 990
  • [35] FUNCTIONAL-ANALYSIS OF P-GLYCOPROTEIN MUTANTS IDENTIFIES PREDICTED TRANSMEMBRANE DOMAIN-11 AS A PUTATIVE DRUG-BINDING SITE
    KAJIJI, S
    TALBOT, F
    GRIZZUTI, K
    VANDYKEPHILLIPS, V
    AGRESTI, M
    SAFA, AR
    GROS, P
    BIOCHEMISTRY, 1993, 32 (16) : 4185 - 4194
  • [36] Sequence requirements of the ATP-binding site within the C-terminal nucleotide-binding domain of mouse P-glycoprotein: Structure-activity relationships for flavonoid binding
    de Wet, H
    McIntosh, DB
    Conseil, G
    Baubichon-Cortay, H
    Krell, T
    Jault, JM
    Daskiewicz, JB
    Barron, D
    Di Pietro, A
    BIOCHEMISTRY, 2001, 40 (34) : 10382 - 10391
  • [37] About a switch: how P-glycoprotein (ABCB1) harnesses the energy of ATP binding and hydrolysis to do mechanical work
    Sauna, Zuben E.
    Ambudkar, Suresh V.
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (01) : 13 - 23
  • [38] Variable expression of P-glycoprotein in the human placenta and its association with mutations of the multidrug resistance 1 gene (MDR1, ABCB1)
    Hitzl, M
    Schaeffeler, E
    Hocher, B
    Slowinski, T
    Halle, H
    Eichelbaum, M
    Kaufmann, P
    Fritz, P
    Fromm, MF
    Schwab, M
    PHARMACOGENETICS, 2004, 14 (05): : 309 - 318
  • [39] Defining the drug-binding site in the human multidrug resistance P-glycoprotein using a methanethiosulfonate analog of verapamil, MTS-verapamil
    Loo, TW
    Clarke, DM
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (18) : 14972 - 14979
  • [40] Determining the dimensions of the drug-binding domain of human P-glycoprotein using thiol cross-linking compounds as molecular rulers
    Loo, TW
    Clarke, DM
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (40) : 36877 - 36880